Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORASMA: Formoterol/Fluticasone vs Alenia in Moderate Asthma
NCT05735431Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of formoterol and fluticasone propionate nasal spray in asthma (2 arms), sponsored by Eurofarma. Primary endpoint: Forced Expiratory Volume in 1 second at 12 weeks. Planned start Jun 2026; status: withdrawn.
02
Drugs
formoterolfluticasone propionate nasal spray
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05735431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735431.